Kornimate/medical-research-clean huggingface dataset:
the effect of mobile-based education given to patients undergoing gynecological oncology surgery on quality of life

Conditions: Gynecologic Cancer

Summary: this study was planned in a randomized controlled prospective experimental design in order to determine the effect of mobile-based education given to patients undergoing gynecological oncology surgery on quality of life. research hypotheses: h1. education given with mobile application in gynecological oncology patients positively affects symptom control of patients. h2. the education given with the mobile application in gynecological oncology patients positively affects the quality of life of the patients.

power analysis was conducted to determine the number of people to be included in the study. the power of the test was calculated with the g\*power 3.1 program. as a result of the power analysis, the sample size should be 50, 25 experimental and 25 control groups, at 95% power, 5% significance level, and 0.690 effect size (df=24; t=1,710). in the research, it was aimed to reach a total of 70 women, 35 people in each group, considering the high power of the test and the losses. introductory information form, symptom evaluation form, functional assessment of cancer therapy-general (fact-g) and turkish-computer system usability questionnaire (t-csuq- sv) planned to be used as data collection tools in the study. the women included in the study sample will be divided into two groups as experimental and control groups according to randomization. experimental group; the group to be trained. control group; this is the group in which no attempt will be made other than data collection. statistical analysis of data: the data obtained in the research will be analyzed using spss (statistical package for social sciences) for windows 25.0 program. homogeneity of descriptive features between groups will be tested by chi-square analysis and independent group t-test. the differentiation status of the scales between the groups will be analyzed with the independent group t-test and the changes within the group will be analyzed with the repeated measures anova test.

Eligibility criteria:
inclusion criteria: * be over 18 years old * able to speak, read and understand turkish * being scheduled for surgery due to a diagnosis of gynecological cancer * having internet access * using a smartphone exclusion criteria: - having a diagnosis of active psychiatric illness

Keywords: gynecological oncology mobile application nursing care
lvsp based crt vs. rvap based crt

Conditions: Heart Failure; Cardiac Resynchronization Therapy; Left Ventricular Septal Pacing; Right Ventricular Septal Pacing

Summary: to find out whether left ventricular septal pacing (lvsp)-based cardiac resynchronization therapy (crt) is superior to right ventricular apical pacing (rvap)-based crt in patients with failed left bundle branch pacing at the beginning of chronic heart failure.


Eligibility criteria:
inclusion criteria: 1. chronic heart failure, lvef ≤35% after at least 3 months of guideline-optimized drug therapy, nyha class ii-iv with complete left bundle branch block (qrsd≥130 ms), or atrioventricular block with lvef ≤ 50% with the indication of cardiac pacing; 3. age between 18 and 90 years old; 4. the expected survival period is greater than 12 months; 5. signed the informed consent form for the study. exclusion criteria: 1. previous mechanical tricuspid valve replacement. 2. previous pacemaker or other devices implanted and for device replacement or upgrading for this time. 3. patients have a history of unstable angina, acute myocardial infarction, cabg, and pci surgery within three months. 4. persistent atrial fibrillation without av block, the proportion of biventricular pacing is not expected to less than 95%. 5. patients participated in any of the other studies at the same time, which may confound the results of this study. 6. pregnancy, planning to become pregnant. 8. patients with a history of heart transplantation.
cholinergic augmentation in frequently falling subjects with parkinson's disease

Conditions: Parkinson's Disease

Summary: the purpose of this study is to find out if a medication that increases levels of a brain chemical called acetylcholine will improve balance and reduce falls in patients with parkinson's disease who have the problem of very poor balance and are frequently falling or nearly falling on a daily basis. donepezil, a drug approved for the treatment of alzheimer's dementia, will reduce falls in subjects with parkinson's disease and balance impairment.

this trial is a double-blinded cross-over design comparing donepezil with placebo in 40 subjects with idiopathic parkinson's disease who report frequent falls or near falls (\>2/week). the purpose of this study is to find out if a medication that increases levels of a brain chemical called acetylcholine will improve balance and reduce falls in patients with parkinson's disease who have the problem of very poor balance and are frequently falling or nearly falling on a daily basis. donepezil, a drug approved for the treatment of alzheimer's dementia, will reduce falls in subjects with parkinson's disease and balance impairment.

Eligibility criteria:
inclusion criteria: * age over 21 * diagnosis of parkinson's disease * treated with dopaminergic medication for at least 1 year exclusion criteria: * must be ambulatory (can use walker or cane) * no obvious remediable cause of falls * falls are on basis of non-cns etiologies (cardiogenic, orthopedic, peripheral neuropathy, etc) * dementia present (mmse \< 25) * not taking cholinergic or anticholinergic medications 10 days prior to screening visit * no warfarin use

Keywords: parkinsons disease falling
bright light on fatigue in women being treated for breast cancer

Conditions: Breast Neoplasms; Breast Cancer; Cancer of Breast; Cancer of the Breast

Summary: this proposed study will examine feasibility and implement therapeutic bright light that is tailored to the individual's circadian typology to estimate its therapeutic effects on sleep/wake patterns and fatigue in breast cancer patients undergoing chemotherapy.


Eligibility criteria:
inclusion criteria: * 21 years of age or older * newly diagnosed with stage i-iii breast cancer * scheduled to receive 21-day cycles of intravenous chemotherapy * experiencing disrupted sleep (determined by pittsburgh sleep quality index) * morning or evening types (determined by horne-ostberg morningness-eveningness questionnaire (meq) * sighted * mentally competent to consent * able to under english exclusion criteria: * concurrent malignancy * undergoing other cancer treatments * engage in shift work or travel across more than 3 time zones within 2 weeks prior to study * known history of seasonal affective disorder or substance abuse * current diagnosis of major axis i psychiatric disorders, neurological impairments, or muscular dystrophies * regularly use steroid or other immunosuppressive medications * take prescribed sedative hypnotics or sleep medications because these conditions may affect fatigue and/or sleep/wake patterns. * have eye conditions (glaucoma or retinal disease), problems triggered by bright light (e.g. migraine), or take photosensitizing medications (e.g. some porphyrin drugs, antipsychotics, antiarrhythmic agents)
an investigation to test a prototype full-face mask in the home setting

Conditions: Sleep Disordered Breathing; Obstructive Sleep Apnea

Summary: this investigation is a prospective non-blinded and non-randomized clinical investigation. this investigation is designed to evaluate the performance (leak and comfort) as well as participant's overall acceptance of the jupiter mask amongst osa participants. a total number of up to 15 osa participants who currently use full face masks will be recruited for the trial.

this investigation is designed to evaluate the performance (leak and comfort) as well as participant's overall acceptance of the jupiter mask amongst osa participants. a total number of up to 15 osa participants who currently use full face masks will be recruited for the trial. the participants will be recruited from the fisher and paykel healthcare database of subjects with osa (ethics reference nty/08/06/064), auckland district health board (adhb), or wellsleep centre (bowen hospital, wellington, nz). participants will be on the trial for 21 days ± 6 days, using the prototypes at home for 14 days ± 3 days. pap baseline data on the participant's prescribed treatment pressure with their usual mask and will be collected for 7 days ± 3 days prior to mask fitting with the jupiter trial mask. fisher and paykel healthcare will act as the investigator and sponsor for this investigation. this study will be conducted in accordance with ich/gcp guidelines. no deviation from the protocol will be implemented without prior review and approval of the sponsor except where it may be necessary to eliminate an immediate hazard to a research participant. in such case, the deviation will be reported to the sponsor (bhavi ogra) as soon as possible.

Eligibility criteria:
inclusion criteria * 18+ years of age * diagnosed with osa by a practicing physician * prescribed pap therapy (bi-level or continuous positive airway pressure (cpap) or automatic positive airway pressure (apap)). patient can be naïve to cpap therapy or experienced (6 months and more) * existing full face mask users * patients who are able to put on and remove their current mask without gross difficulty relating to an existing condition (e.g. arthritis of the hands). exclusion criteria * inability to give informed consent * anatomical or physiological conditions making pap therapy inappropriate (e.g unconsolidated facial fracture) * commercial drivers who are investigated by new zealand transport agency (nzta) * current diagnosis of co2 retention * pregnant or think they may be pregnant
the influence of multi-domain cognitive training on large-scale structural and functional brain networks in mci

Conditions: Mild Cognitive Impairment

Summary: the purpose of this study is to integrate advanced computational techniques and multimodal neuroimaging methods to examine the potential effects of long-term, multi-domain, online, computerized cognitive training on large-scale structural and functional brain networks in older adults with mild cognitive impairment (mci).

this multilevel study will be comprised of a placebo controlled randomized controlled trial to test the effect of long-term (6 months), multi-domain, computerized cognitive training on large-scale structural and functional brain networks in individuals with mci (age \>= 65 years). neuroimaging and neuropsychological data before and after intervention will be evaluated within and between groups to elucidate the trajectory of neuronal network improvements associated with training compared to typical mci development. we will compare the outcomes between participants with mci who receive structured cognitive training (treatment group: tg) with those who receive nonspecific computerized training activities (active controls: ac). the duration of intervention is 6 months. the focus of the study will be on individuals with amnestic mci (single- or multi- domain). the study includes 30 mci subjects in a treatment group (tg) and 30 matched mci subjects in active control (ac) group. tg and ac participants will be evaluated at two time points: 1) baseline and 2) 6-month (post-training).

Eligibility criteria:
inclusion criteria: * cognitive concern by subject, informant or physician * impairment in memory domain (delayed recall of one paragraph from logical memory ii subscale from wechsler memory scale - revised with cutoff scores of \<=8, \<=4 and \<=2 for 16, 8-15 and 0-7 years of education) * essentially normal functional activities * mini-mental state examination (mmse) scores \>=24 * stability of permitted medications (e.g. cholinesterase inhibitors, hypertension medication, etc.) for at least two months. exclusion criteria: * any significant neurological condition including probable dementia, parkinson's disease, huntington's disease, multiple sclerosis, and brain tumor, among others. * presence of axis i disorder * current use of psychoactive medications except for the permitted medications. * claustrophobia * mri contraindication * any significant systemic or unstable medical condition which could lead to difficulty complying with the protocol.
barriers to mental healthcare utilization in parkinson's disease

Conditions: Parkinson's Disease; Depression; Anxiety

Summary: parkinson's disease (pd) is the second most common neurodegenerative disorder in the elderly. in most people, the illness is complicated by co-occurring psychiatric problems such as depression and anxiety. these non-motor concerns negatively affect the course and management of the disease, often leading to poor outcomes for both patients and their families. despite these deleterious consequences, psychiatric symptoms in pd are both underreported by patients as well as under-recognized and under-treated by health care providers. the primary purpose of this study is to identify and describe barriers to mental healthcare utilization for people with parkinson's disease. secondary objectives include the assessment of attitudes and preferences regarding the need for mental health services in the pd community and the acceptability of telehealth interventions as a method for improving access and quality of care. in order to accomplish these aims, participants will be asked to fill out an anonymous survey which will take about 15-30 minutes to complete. to best accommodate pd patients with varying levels of disability, participants will have the option to complete the survey online, on paper, or over the phone. the information obtained from this study will be used to support future treatment development efforts (i.e., phone and internet based interventions, community based trainings with local providers) intended to improve access and quality of mental health care for people with pd. to the best of the investigators knowledge, this is the first study to systematically examine barriers to mental healthcare utilization in pd in a national sample.

the survey may be completed online at https://www.surveymonkey.com/s/improvecare4pd. potential participants may also call dr. dobkin at 732-235-4051 to complete the survey over the phone or to request a paper copy to mailed out.

Eligibility criteria:
inclusion criteria: * diagnosis of parkinson's disease * at least 18 years of age exclusion criteria: * less than 18 years of age we are looking for responses from those who have, as well as those who have not, had mental health treatment in the past.

Keywords: parkinson's disease depression anxiety treatment
focal high-intensity focused ultrasound for primary localized prostate cancer: midterm oncological outcomes

Conditions: Prostate Cancer

Summary: single-center evaluation of all patients treated for primary localized prostate cancer with focal hifu from november 2009 to december 2016. to evaluate midterm oncological outcomes of focal hifu therapy in low an intermediate risk prostate cancer.


Eligibility criteria:
inclusion criteria: * • the patients with low or intermediate risk pca (psa \<20 ng/ml, gleason score 7 or less and clinical stage t2b or less) who received pga/ft using hifu were included. exclusion criteria: * patients who were previously treated with radiotherapy, androgen deprivation therapy (adt) or other treatment for their prostate cancer were excluded.
open bifurcation surgery study

Conditions: Infrarenal Aortic Aneurysm

Summary: different cross clamping techniques in aortic surgery causes different cardiac stress


Eligibility criteria:
inclusion criteria: * aaa \> 5cm exclusion criteria: * emergency cases
stage i her2 positive invasive breast cancer de-escalation study(iris-c/d)

Conditions: Breast Cancer

Summary: this is an open label, phase ii study evaluating the efficacy and safety of trastuzumab combined with oral chemotherapy (capecitabine or vinorelbine) in patients with her-2 positive stage i breast cancer.


Eligibility criteria:
inclusion criteria: * females 18-70 years old; * pathological confirmed of stage i breast cancer: histologically confirmed that the longest diameter of invasive cancer is no more than 2cm and the lymph node is negative (n0); * if a patient is hr negative(er/pr\<10%), the longest diameter of invasive cancer could not exceed 2cm; while if a patient is hr positive(er and/or pr ≥10%）,the longest diameter of invasive cancer is greater than 1cm and no more than 2cm; * the pathological type of immunohistochemistry must meet the following conditions: her-2 (3+) or her-2 (0-2 +) with fish detection is amplified; * for patients with invasive lesions on both sides, if both lesions are her-2 positive and meet the tumor size requirements, then can be enrolled; * has adequate organ function meeting the following criteria: (1) adequate bone marrow function: hemoglobin ≥ 90 g/l (no blood transfusion within 14 days); absolute neutrophil count ≥ 1.5 x 109 /l; platelet count ≥ 100 \* 109 /l; (2)adequate liver and kidney function: alanine aminotransferase (alt) ≤ 3×upper limit of normal (uln), aspartate aminotransferase (ast) ≤ 3×uln, total bilirubin (tbil)≤ 1.5×uln, serum creatinine ≤ 1×uln#and with endogenous creatinine clearance rate of \>50 ml/min (cockcroft-gault formula); * lvef\>50%; * the patient voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up. exclusion criteria: * has received neoadjuvant therapy (include chemotherapy, targeted therapy, radiotherapy or endocrine therapy; * has previous history of additional malignancy, with the exception of adequately treated basal cell carcinoma and cervical carcinoma in situ; * has metastic (stage 4) breast cancer; * pregnant or breast feeding women, or women of childbearing age who cannot practice effective contraceptives; * patients participating in other clinical trials at the same time; * has severe organ dysfunction (cardiopulmonary liver and kidney) insufficiency, left ventricular ejection fraction (lvef) \ 150/90mmhg, myocardial infarction, or cerebral blood vessel); diabetic patients with poor blood glucose control; patients with severe hypertension; * has severe or uncontrolled infection; * has a history of psychotropic substance abuse and were unable to abandon drug habits, or those with history of mental disorders; * the researchers considered patients to be unsuitable for the study.
efficacy of red light in vitiligo

Conditions: Vitiligo

Summary: vitiligo is a chronic acquired disease characterized by well defined white macules and patches affecting the skin. there are many treatment modalities available for vitiligo, however, none of them cure the disease. visible red light has been shown to stimulates melanocyte migration and proliferation resulting in repigmentation of vitiligo patches. however, there are only a few studies published on the efficacy of red light in vitiligo. this is a prospective single-blind randomized clinical trial to assess efficacy of red light in the treatment of vitiligo.

vitiligo is a chronic acquired disease characterized by well defined white macules and patches affecting the skin and mucous membranes. mucocutaneous lesions develop secondary to selective destruction of melanocytes. the etiology of vitiligo is largely unknown but more likely to be multifactorial. there are several theories on the pathogenesis of vitiligo including mainly the autoimmune, neurohormonal, and autocytotoxic theories. the autoimmune hypothesis has the strongest evidence with alteration mainly in the cellular immune response. there are many treatment modalities available for vitiligo, however, none of them cure the disease. these include different topical treatments, phototherapy, surgical therapy, and depigmentation therapy. visible red light has been shown to stimulates melanocyte migration and proliferation resulting in repigmentation of vitiligo patches. however, there are only a few studies published on the efficacy of red light in vitiligo. the investigators plan on conducting a prospective single-blind randomized clinical trial to assess efficacy of red light in the treatment of vitiligo. study objective to evaluate the potential for red light to induce repigmentation within vitiligo patches.

Eligibility criteria:
inclusion criteria: * age \> 18 years. * localized or generalized vitiligo that involves a non mucosal or acral site. * patients should have a patch of at least 25 cm2 that shows no more than 10% repigmentation as assessed visually exclusion criteria: * patients who received treatment for vitiligo within the past 3 weeks. * patients known to have a photosensitivity disorder * history of previous skin cancer. * history of severe medical illness or immunosuppression. * pregnancy or breast-feeding.

Keywords: vitiligo red laser light
study of the application of cpap to reduce complications and improve lung cancer ablation radiofrequency treatment

Conditions: Atelectasis; Lung Cancer

Summary: the project aims to study whether the application of a continuous positive airway pressure (cpap) of 4 cm water vapor is a safe method in pulmonary radiofrequency intervention (prf) lung cancer under conscious sedation compared with placebo. and, assess whether cpap prevents atelectasis formation and consequently reduces the potential complications of prf and improves procedural success


Eligibility criteria:
inclusion criteria: * male and female aged 18 years and older * patient with a scheduled intervention for ablation of pulmonary malignant tumor with radiofrequency . * patient able to undergo tests and examinations required by the study. exclusion criteria: * patients with cpap intolerance test. * patients with progressive disease in which local treatment is not applicable * patients with intercurrent process (pleural effusion, pneumonia, ...). * patient unable to understand the proceedings. * pregnancy or breastfeeding.

Keywords: prevention radiofrequency treatment lung cancer ablation